In addition, custom-designed BMP2 variants with engineered tailored receptor binding affinities for type II and type I receptors can be used as superior Activin A antagonists simultaneously serving as BMP2 super-agonists to potentially overcome bone erosions observed in MM. Here, BMP2 is linked to Miyoshi myopathy.